Category - Executive Moves

Executive Moves

Zosano Pharma names Steven Lo as CEO

Steven Lo Zosano Pharma (NASDAQ:ZSAN) has appointed Steven Lo as president, CEO and a director, effective Oct. 21. Mr. Lo is departing from his role as CCO at Puma Biotechnology (NASDAQ:PUMA), effective Oct. 18, where...

October 8, 2019

Executive Moves

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Canaccord Genuity appointed Edward Nash as its New York office’s managing director, equity research. Mr. Nash completes Canaccord Genuity’s team of five senior biotechnology analysts and will focus on companies...

October 7, 2019

Executive Moves

Cerecin names Lilian Chow as VP of clinical operations and regulatory affairs

Lilian Chow Closely-held Cerecin appointed Lilian Chow as VP of clinical operations and regulatory affairs, responsible for leading Cerecin’s upcoming Phase 3 study of tricaprilin for the treatment of Alzheimer’s...

October 7, 2019

Executive Moves

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharmaceuticals (NASDAQ:HEPA) promoted Daren Ure, Daniel Trepanier and Patrick Mayo to the new roles of CSO; SVP of drug development; and SVP of clinical pharmacology, respectively, to further advance the...

October 3, 2019

Executive Moves

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Bettina Cockroft Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations. Sangamo is using its ex vivo gene-edited cell...

September 30, 2019

Executive Moves

electroCore names Daniel Goldberger as CEO

Daniel Goldberger electroCore (NASDAQ:ECOR) has appointed Daniel Goldberger as CEO, effective Oct. 1. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology industries; with...

September 30, 2019

Executive Moves

Catabasis Pharma names Andrew Komjathy as chief commercial officer

Andrew Komjathy Catabasis Pharmaceuticals (NASDAQ:CATB) appointed Andrew Komjathy as its chief commercial officer. Catabasis’ lead program is edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). The...

September 25, 2019

Executive Moves

BriaCell names immunology expert, Cara Haymaker, to SAB

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed immunology expert, Cara Haymaker, to its scientific advisory board, effective immediately. In addition, Dr. Bill Williams, president and CEO, has been selected to...

September 25, 2019

Executive Moves

MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors

Online continuing professional development provider, MDBriefCase Group (MDBC), is collaborating with Dr. David Strain, senior clinical lecturer at the University of Exeter and Dr. Mohamed Farghaly, associate professor...

September 18, 2019

Executive Moves

Stereotaxis names Kimberly Peery as CFO

Kimberly Peery Stereotaxis (NYSE American:STXS) appointed Kimberly Peery as CFO, effective October 1, replacing Martin Stammer, who has accepted a position as CFO of a large professional services firm in the St. Louis...

September 18, 2019

Category - Executive Moves

Zosano Pharma names Steven Lo as CEO

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Cerecin names Lilian Chow as VP of clinical operations and regulatory affairs

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

electroCore names Daniel Goldberger as CEO

Catabasis Pharma names Andrew Komjathy as chief commercial officer

BriaCell names immunology expert, Cara Haymaker, to SAB

MDBriefCase names Drs. David Strain and Mohamed Farghaly as new expert advisors

Stereotaxis names Kimberly Peery as CFO

General

More